Erleada: Prostate cancer drug reduces risk of spread and death
Key takeaways
- The addition of Erleada also reduced the risk of the cancer spreading or death by 20%, the company said.
- The data, presented at the American Society of Clinical Oncology meeting in Chicago, is likely to change how doctors approach treatment of men with high-risk localized or locally advanced prostate cancer.
- About 40% of the 330,000 people diagnosed with prostate cancer in the U.S. are considered high-risk, J&J said.
Why this matters: local context for readers following news across Pakistan and the region.
Add ARY News on Google AAResize Johnson & Johnson’s prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of disease progression or death, according to data from a late-stage trial presented on Sunday.
The study, which followed patients for over five years, found that those who received the regimen were nine times more likely to have little to no detectable cancer in the prostate at the time of surgery compared with those given testosterone-blocking therapy alone.
The addition of Erleada also reduced the risk of the cancer spreading or death by 20%, the company said.